行情

NTGN

NTGN

Neon Therapeutics
NASDAQ

实时行情|Nasdaq Last Sale

2.175
+0.045
+2.11%
交易中 15:48 10/16 EDT
开盘
2.130
昨收
2.130
最高
2.240
最低
2.090
成交量
9.66万
成交额
--
52周最高
9.70
52周最低
1.610
市值
2,044.45万
市盈率(TTM)
-0.7212
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NTGN 新闻

  • 美联储褐皮书温和下调经济评估 称企业调低前景展望
  • 新浪美股.1小时前
  • 午盘:关注数据与财报 美股窄幅震荡
  • 新浪美股.3小时前
  • 通用汽车与UAW达成临时协议 或将结束为期四周的罢工
  • 新浪美股.4小时前
  • 软银计划向WeWork注资50亿美元 仍不占控股地位
  • 新浪科技.4小时前

更多

所属板块

生物技术和医学研究
+0.18%
制药与医学研究
+0.07%

热门股票

名称
价格
涨跌幅

NTGN 简况

Neon Therapeutics is a clinical-stage immuno-oncology company. The Company is focused on developing therapeutics leveraging neoantigen biology to treat cancer. The Company's neoantigen-based product engine allows it to develop multiple treatment modalities, including vaccines and thymus (T) cell therapies targeting both personalized and shared neoantigens. The Company's neoantigen-based product engine targets both neoantigens that are specific to individual patients, as well as neoantigens that are shared across patients and tumor types. The Company's NEO-PV-01 program is a personalized neoantigen vaccine. NEO-PV-01 utilizes an epitope computational engine called Real-time Epitope Computation for Oncology (RECON). The Company's NEO-PTC-01 is an Adoptive T Cell Therapy. NEO-PTC-01 uses immunogens in co-culture with T cells and monocyte-derived dendritic cells from patients in order to ex vivo stimulate autologous T cells to respond against neoantigen targets.
展开

Webull提供Neon Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。